Abstract
This chapter explores HER-2/neu as a critical target for cancer gene therapy. HER-2/neu gene overexpression is a frequent molecular event in human cancers. Overexpression of HER-2/neu indicates an unfavorable prognosis and is correlated with the low survival rate of patients with multiple cancer types, including breast and ovarian cancer. In humans, the HER-2/neu protooncogene is frequently overexpressed in many types of cancers, including breast, ovarian, lung, stomach, and oral cancers. This suggests that HER-2/neu overexpression plays a critical role in the development of human malignancy. The overall survival rate of cancer patients whose tumors have HER-2/neu overexpression is significantly shorter than for those patients whose tumors do not have HER-2/neu overexpression. Also, overexpression of the proto-oncogene HER-2/neu can lead to cell transformation and is tightly correlated with the development of malignant tumor growth in many tissue types. The results of the animal experiments mentioned in this chapter demonstrate that cationic liposome combined with genes of transcriptional repressors can result in significant therapeutic effects on cancer cells. As gene overexpression is a common mechanism of cancer as well as other types of diseases such as AIDS, the therapeutic strategy discussed in this chapter can have tremendous potential in clinical application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
